Cytochrome P450: what have we learned and what are the future issues?
about
Diversity and function of mutations in p450 oxidoreductase in patients with Antley-Bixler syndrome and disordered steroidogenesisCancer Activation and Polymorphisms of Human Cytochrome P450 1B1Recalling P446. P4501A1 (CYP1A1) opting for clinical applicationEffects of genetic variants of human P450 oxidoreductase on catalysis by CYP2D6 in vitroVariations on a (t)heme--novel mechanisms, redox partners and catalytic functions in the cytochrome P450 superfamilyInfluence of various polymorphic variants of cytochrome P450 oxidoreductase (POR) on drug metabolic activity of CYP3A4 and CYP2B6Identification of amino acid residues involved in 4-chloroindole 3-hydroxylation by cytochrome P450 2A6 using screening of random libraries.Pharmacogenomics of human liver cytochrome P450 oxidoreductase: multifactorial analysis and impact on microsomal drug oxidation.Analysis of epoxyeicosatrienoic acids by chiral liquid chromatography/electron capture atmospheric pressure chemical ionization mass spectrometry using [13C]-analog internal standards.Role of Cytochrome P450 (CYP)1A in Hyperoxic Lung Injury: Analysis of the Transcriptome and Proteome.Mechanisms of differential expression of the CYP2A13 7520C and 7520G alleles in human lung: allelic expression analysis for CYP2A13 heterogeneous nuclear RNA, and evidence for the involvement of multiple cis-regulatory single nucleotide polymorphismMice deficient in the gene for cytochrome P450 (CYP)1A1 are more susceptible than wild-type to hyperoxic lung injury: evidence for protective role of CYP1A1 against oxidative stress.Metabolism and action of proteasome inhibitors in primary human hepatocytesTargeting aldehyde dehydrogenase 2: new therapeutic opportunities.The role of aryl hydrocarbon receptor in the pathogenesis of cardiovascular diseases.Pyranoflavones: a group of small-molecule probes for exploring the active site cavities of cytochrome P450 enzymes 1A1, 1A2, and 1B1.Human CYP4Z1 catalyzes the in-chain hydroxylation of lauric acid and myristic acid.Augmented oxygen-mediated transcriptional activation of cytochrome P450 (CYP)1A expression and increased susceptibilities to hyperoxic lung injury in transgenic mice carrying the human CYP1A1 or mouse 1A2 promoter in vivo.Optimization and validation of a label-free MRM method for the quantification of cytochrome P450 isoforms in biological samples.Simultaneous measurement of CYP1A2 activity, regioselectivity, and coupling: Implications for environmental sensitivity of enzyme-substrate binding.Concentration dependent effects of tobacco particulates from different types of cigarettes on expression of drug metabolizing proteins, and benzo(a)pyrene metabolism in primary normal human oral epithelial cellsPrenatal administration of the cytochrome P4501A inducer, Β-naphthoflavone (BNF), attenuates hyperoxic lung injury in newborn mice: implications for bronchopulmonary dysplasia (BPD) in premature infants.Sex-specific differences in hyperoxic lung injury in mice: role of cytochrome P450 (CYP)1A.Disruption of cytochrome P4501A2 in mice leads to increased susceptibility to hyperoxic lung injury.Novel inhibitor discovery against aromatase through virtual screening and molecular dynamic simulation: a computational approach in drug design7-Ethynylcoumarins: selective inhibitors of human cytochrome P450s 1A1 and 1A2.Life and times in biochemical toxicology.Active-site structure, binding and redox activity of the heme-thiolate enzyme CYP2D6 immobilized on coated Ag electrodes: a surface-enhanced resonance Raman scattering study.NMR in pharmacokinetic and pharmacodynamic profiling.Nitric oxide-dependent proteasomal degradation of cytochrome P450 2B proteinsCytochrome P450s and other enzymes in drug metabolism and toxicity.Genetics of P450 oxidoreductase: sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutations.The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy.The action of cytochrome b(5) on CYP2E1 and CYP2C19 activities requires anionic residues D58 and D65.The growing burden of chronic obstructive pulmonary disease and lung cancer in women: examining sex differences in cigarette smoke metabolism.Expression of cytochrome P450 2A13 in human non-small cell lung cancer and its clinical significance.Proton-pump inhibitor omeprazole attenuates hyperoxia induced lung injury.Evaluation of the modifying effect of inhalation of mainstream cigarette smoke on mouse bladder carcinogenesis.Ginsenoside Rb1 Inhibits Doxorubicin-Triggered H9C2 Cell Apoptosis via Aryl Hydrocarbon Receptor.Production of human phase 1 and 2 metabolites by whole-cell biotransformation with recombinant microbes.
P2860
Q24531477-CA3C1A4B-AC8A-4E11-B34A-56DFDBA526BEQ26749242-1D451133-7C23-4559-AD60-C40287F9E0E3Q28245203-9581EDDF-D135-49FA-BF94-BBF2EF562EC2Q28295439-65DA38D5-1D38-446C-8F49-3FB2F3CE8E89Q28304165-61EC22C2-D526-4F57-A289-70DC7C8084FCQ28484196-C68A8465-3AAD-44B0-B344-32F168904F04Q33382575-12215DCE-5A88-402D-9F2B-7A0CFF82B587Q33431427-16186C8A-E5D5-436A-937A-71A403E0A5E3Q33448255-FC0AB87B-4009-4B98-B9EA-DD74969811B2Q33673517-F8B7C56D-1EDD-46D5-BC3B-B63BE5DB2A95Q33872242-C9A08F5F-C890-4339-8F34-E78097C25776Q34354194-A0CF4704-A2D0-4C2A-A8DC-BDBAF111BE43Q34359489-98C8F102-CEB4-4BA4-ABF6-DCD375422F3CQ34395219-3C25AEAA-F0B3-4643-B0DA-BB0945A561D8Q34552443-36EE2541-258F-4AD0-939C-C1AB6AA59D24Q34677757-522E3B49-D188-492D-B43B-82F893629BA2Q34906403-E64F910C-D139-4455-9AD4-B56224C83F57Q35068300-225FE89E-AC7D-44EC-88AD-C33FE5473A9CQ35192807-99E5F623-0CFD-4A9A-A493-963BCEB18106Q35231748-9DD35E10-5378-4212-B5BF-8BEF50503272Q35239248-37B1DACA-5498-4A4A-9641-34B0E6767060Q35381595-B0336B82-8459-4395-8F1B-845B8BB73671Q35528609-B8C61481-CBFC-4F5E-96A7-768A43A8F70EQ35566747-C830FAB2-DDC5-42CD-97D1-7A768B12048EQ35937856-7D71F834-2F1B-41C4-92B5-BE664F3D9182Q35981085-A623C9A1-EF21-402F-9616-9E79840470F2Q36176231-224CE4E4-B850-4260-B75E-A7C4E6E9FE84Q36177204-D7B3A86A-E85A-47BB-B605-46A809A1C1DCQ36211847-12841FA7-D890-4D97-81C4-485FA5EDEE82Q36343293-887707A5-3BDA-49BA-972A-075EB17AC91FQ36439150-E405E844-5626-4401-91D3-705747944BE8Q36446526-D95E559B-D684-4201-BD94-1B4F78A591BAQ36599937-5643B417-7EDC-4321-AD3C-731645C9314CQ36680194-749EB8D8-5A6A-4AE0-A95D-981D50AF52BDQ36782636-F1C800D9-A58C-4095-9431-295E95223D6BQ36878107-087FB1E9-CAB2-44B1-AE46-C6E2D4BC04D8Q37212073-7A52B971-6A75-4374-A349-CF9B9E4A6CE9Q37579390-5BDA89C0-5E98-4631-AD96-D3D9FD56BB30Q37685108-C0A22900-5F7E-4FAD-8572-0C94A6B6D6E0Q37810229-E79CD40A-D56F-45BE-AAA5-718E24C209C2
P2860
Cytochrome P450: what have we learned and what are the future issues?
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Cytochrome P450: what have we learned and what are the future issues?
@ast
Cytochrome P450: what have we learned and what are the future issues?
@en
type
label
Cytochrome P450: what have we learned and what are the future issues?
@ast
Cytochrome P450: what have we learned and what are the future issues?
@en
prefLabel
Cytochrome P450: what have we learned and what are the future issues?
@ast
Cytochrome P450: what have we learned and what are the future issues?
@en
P2860
P356
P1476
Cytochrome P450: what have we learned and what are the future issues?
@en
P2093
F Peter Guengerich
P2860
P304
P356
10.1081/DMR-120033996
P407
P577
2004-05-01T00:00:00Z